ITGB2 and Keratoconjunctivitis sicca: Due to the effectiveness of inhibiting LFA-1 and the enhanced expression of LFA-1 in dry eye, LtxA therapy may be beneficial to patients suffering from dry eye disease by eliminating these activated LFA-1-expressing cells.